Trastuzumab - Genentech

Drug Profile

Trastuzumab - Genentech

Alternative Names: Anti-c-erbB-2 monoclonal antibody; Anti-erbB-2- monoclonal antibody; Anti-HER-2 monoclonal antibody; Anti-p185HER-2 monoclonal antibody; HER-2; HER-2 human monoclonal antibody; HER-2 MAb; HER-2 monoclonal antibody; HER-2 murine monoclonal antibody; HER-2/neu MAb; HER-2/neu monoclonal antibody; Herceptin; Monoclonal antibody 4D5; R 597; RG597

Latest Information Update: 06 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech; Memorial Sloan-Kettering Cancer Center
  • Developer Chugai Pharmaceutical; Dana-Farber Cancer Institute; European Organisation for Research and Treatment of Cancer; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; Genentech; Medica Scientia Innovation Research; Northwestern University; Roche; Sanofi; West German Study Group
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer
  • Phase II Brain metastases; Colorectal cancer
  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Urogenital cancer

Most Recent Events

  • 31 Oct 2018 Chugai Pharmaceutical withdraws the lawsuits and petitions for provisional disposition order, which were filed independently against Daiichi Sankyo and Pfizer Japan
  • 13 Sep 2018 Registered for Breast cancer (Combination therapy, Early-stage disease, Neoadjuvant therapy) in Canada (SC)
  • 13 Sep 2018 Pharmacokinetics, Efficacy and adverse events data from the phase III HannaH trial in Breast cancer released by Roche
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top